At Chiasma, we are focused on improving the lives of patients who face challenges associated with existing treatments for their rare and debilitating diseases. Employing our Transient Permeability Enhancer (TPE®) technology platform, we are seeking to develop and ultimately commercialize oral medications that are currently only available as injections. We currently are developing octreotide capsules for the potential maintenance treatment of adults with acromegaly.
We are guided every day by our strongly held values:
- Compassion for the patients we serve
- Innovation in applying our proprietary Transient Permeability Enhancer (TPE®) technology platform
- Efficiency in managing our resources and investing in areas where we can have the greatest impact
- Integrity in the way we conduct clinical research, do business and communicate to our diverse audiences